// App-Quantinova.ai

647 : Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Researchers

Presenter

  • Hagop M. Kantarjian

Principal Investigators

  • Elisabetta Abruzzese

  • Jane Apperley

  • Jorge E. Cortes

  • Charles Chuah

  • Daniel J. DeAngelo

  • John F. DiPersio

  • Andreas Hochhaus

  • Jeffrey H. Lipton

  • Franck E Nicolini

  • Javier Pinilla Ibarz

  • Delphine Rea

  • Gianantonio Rosti

  • Philippe Rousselot

  • Neil P Shah

  • Moshe Talpaz

  • Shouryadeep Srivastava

  • Vickie Lu

  • Michael J. Mauro

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • S Eugenio Hospital, Tor Vergata University, Rome, Italy,

  • Centre for Haematology, Imperial Collegel, London, United Kingdom

  • Georgia Cancer Center, Augusta University, Augusta, GA

  • Singapore General Hospital, Duke-NUS Graduate Medical School, Singapore, Singapore

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Washington University School of Medicine, St. Louis, MO

  • Essen University Hospital, Essen, Germany

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Hématologie Clinique,Centre Léon Bérard,Lyon,France

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Hospital Saint Antoine, Paris, France

  • Hospital Saint Antoine, Paris, France

  • Hospital Mignot University de Versailles Saint-Quentin-en-Yvelines,Paris,Frankreich

  • University of California, San Francisco, San Francisco, CA

  • Comprehensive Cancer Center, University of Michigan, Grass Lake, MI

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York

Locations

  • United States

  • Italy

  • United Kingdom

  • Singapore

  • Germany

  • Canada

  • France

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Paraoxonase 1

  • Ph chromosome

Drug/Treatment

  • Ponatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT01207440

  • NCT02467270

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved